期刊文献+

原发性肝脏恶性黑色素瘤的诊治进展 被引量:10

Advances in the diagnosis and treatment of primary malignant melanoma of the liver
原文传递
导出
摘要 恶性黑色素瘤是由皮肤等器官黑色素细胞产生的肿瘤,该病多见于中老年人,其常见发生部位为皮肤、眼部、肛周等,少数可发生于鼻腔、鼻窦、口腔、喉部、脑脊膜、胆囊、消化道、骨、肺、肾上腺等,原发于肝脏的恶性黑色素瘤临床极为罕见。原发性黑色素瘤主要临床表现为肝大、黄疸、消瘦、肝区叩击痛等,表现特异性不强,其诊断需借助于病理学及免疫组织化学染色支持,并结合临床排除其他部位恶性黑色素瘤生长可能。在治疗方面,目前国内外肝脏原发性恶性黑色素瘤无特效的治疗方法。对于单发或肿瘤体积相对较小的个体可考虑积极手术治疗,多发及体积较大者可行放射及化学治疗、免疫调节治疗。但一般情况下,原发性黑色素瘤预后相对较差。 Malignant melanoma is a kind of tumor generated from melanocytes of skin and other organs that often offends old people. The common site for it is the skin,eyes and crissum,and it seldom occurs in the nasal cavity,paranasal sinus,oral cavity,laryngeal,meninges,gallbladder,digestive tube,bone,lung,adrenal. Primary liver malignant melanoma is extremely rare. The main clinical manifestations are hepatomegaly,jaundice,weight loss,liver percussion pain,and the specificity of performance is not strong. The diagnosis should be made with the aid of pathology and immunohistochemistry after other primary origins have been excluded combined with clinic. At present,primary malignant melanoma of the liver is still lack of effective treatment methods. Patients with single or small lesion can be considered aggressive surgery,and patients with multiple and large lesions should be treated by radiotherapy,chemotherapy and immune modulation. But in general,the prognosis is relatively poor.
出处 《中华消化病与影像杂志(电子版)》 2016年第3期133-136,共4页 Chinese Journal of Digestion and Medical Imageology(Electronic Edition)
关键词 恶性黑色素瘤 诊治进展 Liver Malignant melanoma Development of diagnosis and treatment
  • 相关文献

参考文献4

二级参考文献19

  • 1熊芬,李慎秋.皮肤恶性黑素瘤的易感基因[J].国外医学(皮肤性病学分册),2004,30(5):320-322. 被引量:4
  • 2侯麦花,朱文元,卢新政.维生素C与三氧化二砷联用对小鼠恶性黑素瘤Cloundman S91细胞增殖及凋亡的影响[J].临床皮肤科杂志,2003,32(12):700-702. 被引量:3
  • 3高天文,李春英,齐显龙,孙东杰.色痣的再认识[J].中华皮肤科杂志,2004,37(11):680-681. 被引量:7
  • 4雷静,韩丹,王克超.恶性黑色素瘤的CT诊断[J].临床放射学杂志,2006,25(8):727-730. 被引量:13
  • 5Capizzi P J, Donohue J H. Metastic melanoma of the gastrointesinal tract: a review of the literature [ J ]. Compr Ther, 1994,20 (1) :20.
  • 6[4]Kemminer SE,Conradt HS,Nimtz M,et al.Production and molecular characterization of clinical phase Ⅰanti-melanoma mouse IgG3 monoclonal antibody R24[J].Biotechnol Prog,2001,17(5):809-821.
  • 7[7]Kaufmann R,Spieth K,Leiter U,et al.Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma:A Randomized,Phase III,Multicenter Study from the Dermatologic Cooperative Oncology Group[J].J Clin Oncol,2005,23(35):9001-9007.
  • 8[8]Weber RW,O'day S,Rose M,et al.Low-Dose Outpatient Chemobio-therapy With Temozolomide,Granulocyte-Macrophage Colony Stimulating Factor,Interferon-{alpha}2b,and Recombinant Interleukin-2 for the Treatment of Metastatic Melanoma[J].J Clin Oncol,2005,23(31).
  • 9[9]Lawson DH.Choices in adjuvant therapy of melanoma[J].Cancer Co-ntrol,2005,12(4):236-241.
  • 10[13]Berger TG,Dieckmann D,Efferth T,et al.Artesunate in the treatment of metastatic uveal melanoma-first experiences[J].Oncol Rep,2005,14(6):1599-1603.

共引文献23

同被引文献57

引证文献10

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部